These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38414979)

  • 1. Expert Consensus on the Diagnosis and Treatment of
    Xu C; Wang Q; Wang D; Wang W; Fang W; Li Z; Liu A; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Huang L; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Pang F; He Q; Huang J; Wang K; Wu F; Xu B; Wang L; Zhu Y; Lin L; Xie Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Wei J; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Feng Y; Zhang Y; Sun P; Wang H; Ye M; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Yang S; Kang J; Zhang J; Zhang C; Ou J; Shi L; Wang Y; Li B; Zhang Z; Li Z; Liu Z; Yang N; Wu L; Wang H; Jin G; Wang G; Wang J; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Zhu X; Shen Y; Ma S; Wang B; Si L; Song Y; Lu Y; Chen J; Song Z
    Glob Med Genet; 2024 Jan; 11(1):86-99. PubMed ID: 38414979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.
    Nagasaka M; Ou SI
    Trends Cancer; 2022 Mar; 8(3):242-258. PubMed ID: 34996744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
    Trombetta D; Sparaneo A; Fabrizio FP; Di Micco CM; Rossi A; Muscarella LA
    Expert Opin Ther Targets; 2021 Oct; 25(10):865-875. PubMed ID: 34706602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
    Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
    Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients.
    Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
    Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful targeting of the
    Wu X; Zhang D; Shi M; Wang F; Li Y; Lin Q
    Ann Transl Med; 2021 Oct; 9(19):1507. PubMed ID: 34805369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
    Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
    Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
    Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
    Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.
    Zhang C; Mei W; Zeng C
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188707. PubMed ID: 35247506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
    Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
    Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent
    Trombetta D; Graziano P; Scarpa A; Sparaneo A; Rossi G; Rossi A; Di Maio M; Antonello D; Mafficini A; Fabrizio FP; Manzorra MC; Balsamo T; Centra F; Simbolo M; Pantalone A; Notarangelo M; Parente P; Lucia Dimitri MC; Bonfitto A; Fiordelisi F; Storlazzi CT; L'Abbate A; Taurchini M; Maiello E; Fazio VM; Muscarella LA
    Oncotarget; 2018 Feb; 9(11):9661-9671. PubMed ID: 29515761
    [No Abstract]   [Full Text] [Related]  

  • 13. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Novel
    Ou SI; Xiu J; Nagasaka M; Xia B; Zhang SS; Zhang Q; Swensen JJ; Spetzler D; Korn WM; Zhu VW; Liu SV
    JTO Clin Res Rep; 2021 Feb; 2(2):100132. PubMed ID: 34589990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD74-NRG1 fusions in lung adenocarcinoma.
    Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
    Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.
    Fernandez-Cuesta L; Thomas RK
    Clin Cancer Res; 2015 May; 21(9):1989-94. PubMed ID: 25501131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
    Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
    J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
    Chen K; Li W; Xi X; Zhong J
    Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
    Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
    J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.